NEULANDLAB

Neuland Laboratories Share Price

₹13,702.35 +264.8 (1.97%)

28 Dec, 2024 02:16

SIP TrendupStart SIP in NEULANDLAB

Start SIP

Performance

  • Low
  • ₹13,453
  • High
  • ₹13,838
  • 52 Week Low
  • ₹5,021
  • 52 Week High
  • ₹18,100
  • Open Price₹13,508
  • Previous Close₹13,438
  • Volume35,695

Investment Returns

  • Over 1 Month -8.29%
  • Over 3 Month + 10.61%
  • Over 6 Month + 88.54%
  • Over 1 Year + 157.09%
SIP Lightning

Smart Investing Starts Here Start SIP with Neuland Laboratories for Steady Growth!

Invest Now

Neuland Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 62.9
  • PEG Ratio
  • 12.4
  • Market Cap Cr
  • 17,580
  • P/B Ratio
  • 13.8
  • Average True Range
  • 755.84
  • EPS
  • 205.86
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -117.85
  • RSI
  • 35.8
  • MFI
  • 11.07

Neuland Laboratories Financials

Neuland Laboratories Technicals

EMA & SMA

Current Price
₹13,702.35
+ 264.8 (1.97%)
pointer
  • stock-down_img
  • Bullish Moving Average 5
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹14,895.59
  • 50 Day
  • ₹14,705.21
  • 100 Day
  • ₹13,426.33
  • 200 Day
  • ₹11,204.63

Resistance and Support

13664.17 Pivot Speed
  • R3 14,260.68
  • R2 14,049.12
  • R1 13,875.73
  • S1 13,490.78
  • S2 13,279.22
  • S3 13,105.83

What's your outlook on Neuland Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Neuland Laboratories is a leading pharmaceutical company specializing in the manufacturing of active pharmaceutical ingredients (APIs) and custom manufacturing solutions. It serves global pharmaceutical companies with high-quality APIs for critical therapeutic areas, including cardiovascular and central nervous system.

Neuland Laboratories has an operating revenue of Rs. 1,528.28 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 26% is great, ROE of 23% is exceptional. The company has a reasonable debt to equity of 4%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 30% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 88 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 57 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and relative strength but it needs to see some buyer interest to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Neuland Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-06 Quarterly Results
2024-08-01 Quarterly Results
2024-05-10 Audited Results & Final Dividend
2024-02-08 Quarterly Results
2023-11-07 Quarterly Results
Date Purpose Remarks
2022-07-15 FINAL Rs.5.00 per share(50%)Final Dividend

Neuland Laboratories F&O

Neuland Laboratories Shareholding Pattern

32.64%
4.04%
0.4%
26.46%
26.5%
9.96%

About Neuland Laboratories

  • NSE Symbol
  • NEULANDLAB
  • BSE Symbol
  • 524558
  • ISIN
  • INE794A01010

Similar Stocks to Neuland Laboratories

Neuland Laboratories FAQs

Neuland Laboratories share price is ₹13,702 As on 28 December, 2024 | 02:02

The Market Cap of Neuland Laboratories is ₹17580 Cr As on 28 December, 2024 | 02:02

The P/E ratio of Neuland Laboratories is 62.9 As on 28 December, 2024 | 02:02

The PB ratio of Neuland Laboratories is 13.8 As on 28 December, 2024 | 02:02

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23